Editorial Policy

GLPTree relies on primary sources wherever a claim can be traced to one. We do not treat secondary sources — news articles, press releases from third parties, or aggregator sites — as evidence for clinical claims. Secondary sources may point us toward a primary source, but the primary source itself must be located and reviewed before a claim is published.

Our accepted primary sources are:

• FDA prescribing information (package inserts): For all dosing, indication, contraindication, and labeled safety data on approved medications. We link directly to the current label on DailyMed (the NIH/NLM prescribing information database) or the FDA drug label repository.
• Peer-reviewed journal publications: For clinical trial efficacy and safety data. We prefer the primary publication of pivotal trials (STEP, SURMOUNT, SCALE, PIONEER, TRIUMPH, and similar programs) in journals such as the New England Journal of Medicine, The Lancet, JAMA, Diabetes Care, and Obesity. Where trial data appears in conference abstracts before full publication, we note this explicitly and update the citation when the full paper is published.
• ClinicalTrials.gov: For trial registration details, protocol information, and primary completion data on ongoing or recently completed studies.
• Manufacturer press releases for trial data: Acceptable only for announcing top-line results from trials that have not yet been published. We cite the press release explicitly, note the date, and note that data has not yet been peer-reviewed. We update these references when peer-reviewed data becomes available.
• Official regulatory body documents: European Medicines Agency (EMA) product assessments, Health Canada monographs, and equivalent official documents from other regulatory bodies.

We do not use Wikipedia, patient advocacy organization summaries, pharma marketing materials, or unattributed blog posts as sources for clinical or dosing claims.

Every quantitative claim on this site — a trial efficacy percentage, a dosing interval, a labeled contraindication — must be traceable to a specific passage in a primary source. The verification process works as follows:

• Numeric claims link to source: When a page states that a trial showed a particular weight-loss outcome, the number is hyperlinked to the specific journal article, FDA label, or trial registry record that contains it. If a link is absent on a page that contains quantitative claims, that is an editorial error we want to correct.
• Trial data cites the published paper: For any clinical trial result, we cite the full reference — authors, journal, year, DOI or PubMed ID — not just a brand name or a news headline.
• Dosing data cross-referenced against the FDA label: Any dosing schedule or administration instruction on GLPTree is cross-referenced against the current FDA-approved prescribing information. If the label has been updated, the page must be updated to reflect the current label before publication or at the next scheduled review.
• Labeling for unapproved or investigational medications: Medications that are not yet FDA-approved (such as retatrutide or cagrisema as of this page's last review date) are clearly identified as investigational. Efficacy and safety claims for these medications cite only peer-reviewed trial publications or ClinicalTrials.gov records.

Every page on GLPTree displays a visible "Last reviewed" date. This date reflects the most recent human review of that page's content, not the original publication date.

Medication pages (brand pages, dosage pages, side-effect pages, comparison pages) are reviewed on the following schedule:

• Quarterly review: Every medication page is reviewed at minimum once per calendar quarter to check for new FDA label changes, significant new trial publications, or updated safety communications.
• On new FDA action: Any FDA action that affects a medication covered on the site — new approval, new indication, label update, safety warning, market withdrawal — triggers an immediate review of all affected pages, regardless of the quarterly cycle.
• On major new trial publication: Publication of a primary outcome paper from a pivotal clinical trial (or a significant secondary analysis) triggers a review of affected pages within 14 days of publication.

Articles, calculators, and informational pages are reviewed annually or when a significant change in clinical evidence warrants earlier review. The relevant last-reviewed date on each page reflects when the most recent review occurred.

We take factual errors seriously. If a page states something that is incorrect — wrong efficacy figure, wrong dosing interval, wrong approval status — we want to know and we want to fix it promptly.

How to submit a correction: Email info@glptree.com with the subject line "Correction — [page name]." Include the specific claim you believe is incorrect, what the correct information is, and a link to the primary source that supports the correction. We aim to respond within 5 business days.

How corrections are logged: When a substantive factual correction is made to a page, the correction is documented at the bottom of that page in a "Corrections" section. The log entry includes the date of correction, a plain description of what was changed (e.g., "Updated Phase 2 weight-loss figure from X% to Y% to reflect the published NEJM paper"), and a link to the correcting source. The page's last-reviewed date is also updated.

Minor corrections — typographical errors, formatting issues, broken links — are corrected without a logged entry but the last-reviewed date is updated. Significant factual corrections are always documented.

GLPTree has no financial relationship with any pharmaceutical manufacturer, biotech company, compounding pharmacy, or telehealth service. The site does not accept paid placements, sponsored content, native advertising, or branded partnerships of any kind related to medications or healthcare services.

The site does not participate in affiliate programs that pay commissions for medication purchases, prescription referrals, or telehealth sign-ups. No link on this site earns a referral fee when clicked.

The site is funded by display advertising served by Google AdSense. Google selects ads based on page content and user browsing history; the publisher has no control over which specific ads appear and receives no information about individual ad clicks. The presence of any ad on this site is not an endorsement of that advertised product or service.

If GLPTree ever accepts a sponsorship, that relationship will be disclosed with the specific text "Sponsored by [name]" on every page or post where sponsored content appears, in addition to a disclosure on this page.

Every page on GLPTree is human-verified against primary sources before publication. This is the core editorial standard of the site, and it is the standard that determines what gets published, what gets revised, and what gets removed.

Verification means a human editor reads each clinical, dosing, or medical claim on the page, locates the primary source that supports it (FDA prescribing information, peer-reviewed publication, ClinicalTrials.gov record, or manufacturer press release for top-line trial data), and confirms that the source actually supports the claim as worded. If a claim cannot be verified to a primary source, it is either rewritten, sourced, or removed. Pages covering clinical or dosing information are additionally subject to medical review by credentialed clinicians as described in our Medical Review Process.

Tools used in editorial production. Like most modern publishers, GLPTree uses a range of software tools in the editorial workflow — including spell-check, grammar tools, citation managers, code editors, and modern large-language-model writing assistants. These tools may help with first drafts, outlines, summarization of long regulatory documents, formatting, and HTML production. They do not make editorial decisions. They do not substitute for primary-source verification. They do not publish to the site. A human editor reviews and verifies every clinical claim against its cited source before publication, and a human is accountable for every page on the site.

This standard applies uniformly to all content on GLPTree, including medication pages, articles, comparison tools, and calculator methodology explanations. The bar for publication is the same regardless of how a draft was produced: every claim sourced, every source verified, every page reviewable.

GLPTree is founded and published by Rolando Valenzuela, an independent web developer and publisher based in Port Saint Lucie, Florida. Rolando is not a licensed healthcare professional. All content published on GLPTree is labeled as educational information, is sourced to primary references, and is subject to medical review for pages covering clinical claims about medications.

Medical reviewers who contribute to GLPTree are board-certified physicians in relevant specialties (obesity medicine, endocrinology, internal medicine). Their credentials and any relevant disclosures are listed on the Medical Review Process page. Medical reviewers review content for factual accuracy against published clinical evidence; they do not provide personalized medical advice and their review does not create a doctor-patient relationship with any reader.

Guest contributors, if any are ever invited, must disclose all relevant conflicts of interest before their content is published. Any conflicts that could reasonably affect the objectivity of the content are disclosed to readers on the relevant page.